Detection of biomarker and development for new combination therapy for anti-EGFR monoclonal antibody cetuximab in lung cancer
| Project/Area Number |
24790811
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 非閉塞性肺疾患癌 / 分子標的治療 |
|---|
| Research Abstract |
This study is basic research that explore the biomarker and factors overcoming drug resistance to anti-EGFR monoclonal antibody cetuximab in lung cancer. We found that KREMEN1 gene was overexpressed and Wnt signaling pathway was highly activated in cetuximab resistant cells. Therefore the inhibition of Wnt signaling pathway can possibility overcome the acquired resistance for cetuximab. Moreover this results can be applicable for lung cancer that is inherently resistance for cetuximab.
|
Report
(3 results)
Research Products
(3 results)
